Abbott's hepatitis C drugs perform well in 2 small trials

04/4/2012 | Wall Street Journal, The

A midstage trial showed that Abbott Laboratories' protease inhibitor ABT-450, in combination with polymerase inhibitor ABT-333 and existing drug ribavirin, suppressed the hepatitis C virus 12 weeks after treatment ended in more than 90% of treatment-naive patients and 47% of patients who didn't respond to prior treatment. In another Phase II study, 10 of 11 patients who received ABT-450 along with Abbott's polymerase inhibitor ABT-072 and ribavirin showed a sustained virologic response 24 weeks after treatment ended. Abbott hopes to take forward some combination of the drugs used in the studies into Phase III testing next year.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL